INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
